Removing barriers to appropriate migraine treatment

Formulary limitations and triptan package size

Stephen D. Silberstein, David William Dodick, Jim Kesslick

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The main goals in the pharmacologic management of migraine headache are to avert or relieve debilitating pain, prevent escalating acute medication use, and improve day-to-day functioning. This review will examine the evidence supporting the early use of acute medication, usually when pain is mild, to enhance patient outcomes. We will also discuss imposed quantity limits as a practical impediment to the implementation of this strategy in the managed care setting, and will identify strategies for overcoming this barrier to effective care. Quantity limits imposed on triptan therapy by health plans can hinder the optimal acute treatment of migraine. A standard triptan quantity limit sufficient to permit early migraine treatment and a movement by manufacturers to provide blister packs consistent with a standard quantity limit should reduce patients costs, permit brand mobility when appropriate, and bolster long-term cost effectiveness by removing an important impediment to the use of triptans when they are most effective, early in the migraine attack when pain is often still mild.

Original languageEnglish (US)
Pages (from-to)1250-1254
Number of pages5
JournalHeadache
Volume45
Issue number9
DOIs
StatePublished - 2005

Fingerprint

Tryptamines
Formularies
Migraine Disorders
Pain
Managed Care Programs
Therapeutics
Blister
Cost-Benefit Analysis
Costs and Cost Analysis
Health

Keywords

  • Formulary
  • Managed care
  • Migraine
  • Pharmacoeconomics
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Removing barriers to appropriate migraine treatment : Formulary limitations and triptan package size. / Silberstein, Stephen D.; Dodick, David William; Kesslick, Jim.

In: Headache, Vol. 45, No. 9, 2005, p. 1250-1254.

Research output: Contribution to journalArticle

Silberstein, Stephen D. ; Dodick, David William ; Kesslick, Jim. / Removing barriers to appropriate migraine treatment : Formulary limitations and triptan package size. In: Headache. 2005 ; Vol. 45, No. 9. pp. 1250-1254.
@article{1a4f845677ea439e9ea0eedc1e3246d3,
title = "Removing barriers to appropriate migraine treatment: Formulary limitations and triptan package size",
abstract = "The main goals in the pharmacologic management of migraine headache are to avert or relieve debilitating pain, prevent escalating acute medication use, and improve day-to-day functioning. This review will examine the evidence supporting the early use of acute medication, usually when pain is mild, to enhance patient outcomes. We will also discuss imposed quantity limits as a practical impediment to the implementation of this strategy in the managed care setting, and will identify strategies for overcoming this barrier to effective care. Quantity limits imposed on triptan therapy by health plans can hinder the optimal acute treatment of migraine. A standard triptan quantity limit sufficient to permit early migraine treatment and a movement by manufacturers to provide blister packs consistent with a standard quantity limit should reduce patients costs, permit brand mobility when appropriate, and bolster long-term cost effectiveness by removing an important impediment to the use of triptans when they are most effective, early in the migraine attack when pain is often still mild.",
keywords = "Formulary, Managed care, Migraine, Pharmacoeconomics, Triptans",
author = "Silberstein, {Stephen D.} and Dodick, {David William} and Jim Kesslick",
year = "2005",
doi = "10.1111/j.1526-4610.2005.00250.x",
language = "English (US)",
volume = "45",
pages = "1250--1254",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Removing barriers to appropriate migraine treatment

T2 - Formulary limitations and triptan package size

AU - Silberstein, Stephen D.

AU - Dodick, David William

AU - Kesslick, Jim

PY - 2005

Y1 - 2005

N2 - The main goals in the pharmacologic management of migraine headache are to avert or relieve debilitating pain, prevent escalating acute medication use, and improve day-to-day functioning. This review will examine the evidence supporting the early use of acute medication, usually when pain is mild, to enhance patient outcomes. We will also discuss imposed quantity limits as a practical impediment to the implementation of this strategy in the managed care setting, and will identify strategies for overcoming this barrier to effective care. Quantity limits imposed on triptan therapy by health plans can hinder the optimal acute treatment of migraine. A standard triptan quantity limit sufficient to permit early migraine treatment and a movement by manufacturers to provide blister packs consistent with a standard quantity limit should reduce patients costs, permit brand mobility when appropriate, and bolster long-term cost effectiveness by removing an important impediment to the use of triptans when they are most effective, early in the migraine attack when pain is often still mild.

AB - The main goals in the pharmacologic management of migraine headache are to avert or relieve debilitating pain, prevent escalating acute medication use, and improve day-to-day functioning. This review will examine the evidence supporting the early use of acute medication, usually when pain is mild, to enhance patient outcomes. We will also discuss imposed quantity limits as a practical impediment to the implementation of this strategy in the managed care setting, and will identify strategies for overcoming this barrier to effective care. Quantity limits imposed on triptan therapy by health plans can hinder the optimal acute treatment of migraine. A standard triptan quantity limit sufficient to permit early migraine treatment and a movement by manufacturers to provide blister packs consistent with a standard quantity limit should reduce patients costs, permit brand mobility when appropriate, and bolster long-term cost effectiveness by removing an important impediment to the use of triptans when they are most effective, early in the migraine attack when pain is often still mild.

KW - Formulary

KW - Managed care

KW - Migraine

KW - Pharmacoeconomics

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=33644873543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644873543&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2005.00250.x

DO - 10.1111/j.1526-4610.2005.00250.x

M3 - Article

VL - 45

SP - 1250

EP - 1254

JO - Headache

JF - Headache

SN - 0017-8748

IS - 9

ER -